glp-1 obesity drugs pipeline The GLP-1 race is entering a new era. It's no longer just Anti-Obesity Drugs – Pharma Companies

Kimberly Anne Gudzune of @HopkinsMedicine, recorded @SocietyGIM #SGIM23 in Denver, Colorado Show Segments Intro Barriers to treating medicine in primary care Patient counseling and obesity pathophysiology Motivational Interviewing Telemedicine for obesity Tools and tips for a weight loss program Medications for Obesity GLP1 agonist prescribing tips Outro Obesity Medicine Pearls Obesity is a chronic disease

FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections

Tirzepatide Once Weekly for the Treatment of Obesity AMG 133 is a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule

One of four subjects showed in vivo GLP-1R expression by human metastatic castration-resistant prostate cancer (mCRPC), avid for prostate specific membrane antigen (PSMA) and Ex-4, according to Stein et al

For researchers evaluating peptide options for weight loss , the speed factor may be as important as the total magnitude of effect

doi: 10.1186/s13048-020-00670-3 126 WangYXiaoHLiuYTongQYuYQiBet al